IP Library Granted Patent US 8,026,376
Granted Patent B2
US 8,026,376 · App. 11/572,333 · Granted Sep 27, 2011

Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoicacid calcium salt (2:1)

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,026,376
App. No.
11/572,333
Granted
Sep 27, 2011
Kind
B2
Abstract

Novel forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4 -[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form XX, Form XXI, Form XXII, Form XXIII, Form XXIV, Form XXV, Form XXVI, Form XXVII, Form XXVIII, Form XXIX, and Form XXX, characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (BPH) and Alzheimer's disease.

Claims (6)

1. A Form XXII atorvastatin calcium having an X-ray powder diffraction containing the following 2θ values measured using CuK a radiation: 4.0, 8.0, 10.0, 13.5, 16.1, 16.4, 17.0, 17.4, 19.2, 20.0, and 20.3.

2. A Form XXII atorvastatin calcium having an X-ray powder diffraction containing the following 2θ values measured using CuK a radiation: 10.0, 16.1, and 19.2, and a solid state 19 F nuclear magnetic resonance having the following chemical shifts expressed in parts per million: −112.0, −114.8, and −118.9.

3. A Form XXII atorvastatin calcium having an X-ray powder diffraction containing the following 2θ values measured using CuK a radiation: 4.0, 4.9, 8.0, 10.0, 11.1, 11.7, 12.2, 13.1, 13.5, 14.0, 14.8, 16.1, 16.4, 17.0, 17.4, 17.7, 19.2, 20.0, 20.3, 21.3, 22.6, 24.5, 27.0, 28.1, 28.9, and 29.4.

4. A Form XXII atorvastatin calcium having a solid state 13 C nuclear magnetic resonance having the following chemical shifts expressed in parts per million: 182.1, 166.6, 164.1, 161.8, 143.7, 139.4, 136.1, 134.2, 129.1, 123.4, 119.7, 115.7, 68.7, 45.1, 43.9, 39.1, 37.4, 26.8, 22.7, 20.6, and 18.3.

5. A Form XXII atorvastatin calcium characterized by Raman spectroscopy having the following peaks expressed in cm −1 : 618, 820, 855, 998, 1033, 1157, 1243, 1364, 1410, 1526, 1603, 1671, and 3059.

6. A Form XXII atorvastatin calcium a solid state 19 F nuclear magnetic resonance having the following chemical shifts expressed in parts per million: −112, −114.8, −118.9.

Assignments (2)
CHANGE OF NAME Recorded Oct 31, 2022
From: UPJOHN US 1 LLC
To: VIATRIS SPECIALTY LLC.
Reel/Frame 061808/0420 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2020
From: WARNER-LAMBERT COMPANY LLC
To: UPJOHN US 1 LLC
Reel/Frame 054293/0956 →